VENUSREM / NSE / Biotechnology & Drugs

Venus Remedies

INR 1,633.5Not available (5.00%) 1D

Last updated: 2026-06-04T19:16:35.368227+00:00

Price Chart

1Y Price Trend

OpenNot available

HighNot available

LowNot available

CloseNot available

VolumeNot available

ChangeNot available

Change %Not available

OHLC data unavailablePrice candles will render once this stock has historical data.

Key Information

Ticker SymbolVENUSREM

Current Price1,633.5

52-Week High1,555.8

52-Week Low415.4

Market Cap2,188.31

Beta0.85

Volume0.12

ISININE411B01019

Day High1,637.1

Day Low1,559.15

Open1,637.1

Recommendations

Target High1,559.15

Target Low417.65

Target Mean0

Target Median0

Risk Metrics

Overall RiskHigh risk

Board Risk54.94

Key Analysis

Overall score, performance score, return rating, defensive, aggressive, and balanced views.

Download app

Projection Analytics

Best-case, base-case, worst-case, and dynamic AI projection views.

Download app

News

Latest stock news

Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 9 December 2025Time unavailable

Market news

Sumeet Bagadia recommends five breakout stocks to buy today - Latent View Analytics, Cantabil Retail India Limited, Gujarat Ambuja Exports, Venus Remedies, and Jindal Stainless.

Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 15 July 2025Time unavailable

Market news

Sumeet Bagadia recommends five breakout stocks to buy today: CEAT, V I P Industries, Blue Jet Healthcare, HEG, and Venus Remedies.

Venus Remedies stock jumps over 14% to 8-week high on FDA approval for anti-mircrobial resistance therapyTime unavailable

Market news

Shares of Venus Remedies rose 14.3% to ₹ 356.65 after the US FDA granted QIDP designation to its product VRP-034, targeting bloodstream infections. This designation offers regulatory benefits, highlighting the need for safer polymyxin therapies. The stock has rebounded 12% this month.

Smallcap pharma stock hits over 8% upper circuit after securing marketing nod for chemotherapy drugs; do you own?Time unavailable

Market news

Venus Remedies gained over 8 per cent today after securing marketing authorisation for three variants of chemotherapy drugs in Israel and Colombia

Venus Remedies shares locked at 5% upper circuit as German arm gets Spanish regulator nod to market Meropenem in SpainTime unavailable

Market news

Venus Remedies' German subsidiary Venus Pharma GmbH has received this approval for 500mg, 1g and 2g injections of this last-recourse antibiotic.